The Chicago Entrepreneur

How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi

Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly’s diabetes injection Mounjaro and obesity drug Zepbound.

Previous post Treasury, IRS unveil plan to close ‘major tax loophole’ used by large partnerships
Next post Cannabis company Columbia Care to cut costs and sell its Florida business